Literature DB >> 18729063

ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.

Elena Quaglino1, Cristina Mastini, Guido Forni, Federica Cavallo.   

Abstract

The epidermal growth factor receptor belongs to a superfamily of receptor tyrosine kinases (RTK) that includes ErbB2. ErbB2 is involved in normal physiological processes, such as embryogenesis, cell proliferation, differentiation, adhesion motility, and apoptosis, while its malfunction or overexpression is responsible for development defects, diabetes, and cancer. The human ortholog of ErbB2 is referred as Her-2 (human ErbB2) while the rat ortholog is referred as neu (rat ErbB2). As ErbB2 is directly involved in carcinogenesis, mice transgenic for the rat neu oncogene allow straightforward assessment of the ability of drugs and vaccines to inhibit the progression of neu-driven cancer. Information from this model may provide indications on the efficacy of similar treatments in patients. This commentary provides key information regarding the use of these transgenic mouse models for evaluation of the efficacy of anti-tumor strategies. Copyright 2008 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729063     DOI: 10.1002/0471142735.im2009s82

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  25 in total

1.  A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors.

Authors:  Maddalena Arigoni; Giuseppina Barutello; Stefania Lanzardo; Dario Longo; Silvio Aime; Claudia Curcio; Manuela Iezzi; Yujuan Zheng; Irmeli Barkefors; Lars Holmgren; Federica Cavallo
Journal:  Angiogenesis       Date:  2012-03-17       Impact factor: 9.596

2.  Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Authors:  Regine M Schoenherr; Karen S Kelly-Spratt; ChenWei Lin; Jeffrey R Whiteaker; Tao Liu; Ted Holzman; Ilsa Coleman; Li-Chia Feng; Travis D Lorentzen; Alexei L Krasnoselsky; Pei Wang; Yan Liu; Kay E Gurley; Lynn M Amon; Athena A Schepmoes; Ronald J Moore; David G Camp; Lewis A Chodosh; Richard D Smith; Peter S Nelson; Martin W McIntosh; Christopher J Kemp; Amanda G Paulovich
Journal:  Proteomics Clin Appl       Date:  2011-02-15       Impact factor: 3.494

3.  The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.

Authors:  Mohammad W Khan; Abdulrahman Saadalla; Ahmed H Ewida; Khalid Al-Katranji; Ghadier Al-Saoudi; Zachary T Giaccone; Fotini Gounari; Ming Zhang; David A Frank; Khashayarsha Khazaie
Journal:  Cancer Immunol Immunother       Date:  2017-09-05       Impact factor: 6.968

4.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

5.  Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer.

Authors:  Alex E Grill; Komal Shahani; Brenda Koniar; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

6.  Adaptive Immune Responses and HER2/neu Positive Breast Cancer.

Authors:  Eric D Mortenson; Yang-Xin Fu
Journal:  Curr Pathobiol Rep       Date:  2013-03

7.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

8.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Authors:  Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling
Journal:  J Transl Med       Date:  2010-06-07       Impact factor: 5.531

Review 9.  Evolution of animal models in cancer vaccine development.

Authors:  Wei-Zen Wei; Richard F Jones; Csaba Juhasz; Heather Gibson; Jesse Veenstra
Journal:  Vaccine       Date:  2015-08-01       Impact factor: 3.641

10.  Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.

Authors:  Cristina Marchini; Cristina Kalogris; Chiara Garulli; Lucia Pietrella; Federico Gabrielli; Claudia Curcio; Elena Quaglino; Federica Cavallo; Augusto Amici
Journal:  Front Oncol       Date:  2013-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.